Omics-based Clinical Trials Market To witness Huge Expansion By 2030

Omics-based Clinical Trials Market Summary

The global omics-based clinical trials market was valued at USD 32.64 billion in 2024 and is anticipated to reach USD 51.77 billion by 2030, expanding at a compound annual growth rate (CAGR) of 8.02% from 2025 to 2030. The market growth is primarily driven by rapid advancements in omics technologies, the rising demand for personalized medicine, significant investments by pharmaceutical companies to improve drug development efficiency, and the support of favorable regulatory frameworks. These factors are collectively propelling the adoption of omics-based strategies in clinical trials to enhance the precision and efficacy of treatments.

Technological innovations such as next-generation sequencing (NGS) and high-throughput screening techniques have drastically reduced the cost and duration of genomic data analysis. These cutting-edge tools allow researchers to perform large-scale studies with greater accuracy and speed, facilitating the detection of genetic markers and disease-related variations. Additionally, increasing strategic collaborations and initiatives by key industry players are positively influencing market expansion. Many companies are actively optimizing their genomic workflows to enhance throughput and reduce turnaround time in genomic sample processing, thus improving overall clinical trial efficiency.

Key Market Trends & Insights

• The phase III segment emerged as the leading phase in the market in 2024, contributing 54.5% of the total revenue share. This dominance is attributed to the increased number of phase III clinical trials, which involve large populations and incur high costs. On average, the median cost for a single phase III trial exceeds USD 19.0 million, underscoring the substantial financial investment required. These trials are essential for validating the safety and efficacy of new treatments, and their rigorous nature is a significant contributor to market growth.
• By study design, the interventional studies segment dominated the market in 2024. This dominance is due to the growing trend of using personalized interventions derived from omics technologies. Interventional studies often include larger patient groups, improving statistical validity and providing a clearer picture of the link between specific biomarkers and treatment outcomes. These studies are central to precision medicine efforts, offering more targeted therapeutic approaches based on a patient’s genetic makeup.
• In terms of therapeutic area, the oncology segment led the market in 2024. This was primarily due to the increasing global burden of cancer and the urgent need for advanced, personalized treatment strategies. According to a January 2024 report by the American Cancer Society, the U.S. alone is expected to witness 2,001,140 new cancer cases and 611,720 cancer-related deaths, emphasizing the demand for more effective oncology-focused clinical trials incorporating omics technologies.
• North America dominated the global omics-based clinical trials market, accounting for 38.0% of the total revenue share in 2024. This regional growth is attributed to the presence of major industry players, robust healthcare infrastructure, and a significant number of ongoing clinical trials. These factors, combined with strong regulatory support and access to advanced technologies, reinforce North America’s leadership in the market.
• The United States is a key contributor to North America’s dominance, with market growth driven by a growing emphasis on personalized medicine. Healthcare providers and researchers in the U.S. are increasingly relying on genomic, proteomic, and metabolomic datasets to develop individualized treatment plans. This shift toward data-driven medicine is fostering innovation and adoption of omics technologies in clinical trials.
• In Europe, the omics-based clinical trials market is poised for considerable growth during the forecast period. This growth is largely due to the expansion of outsourcing activities among pharmaceutical and biotech companies. Increasing collaborations and strategic partnerships across the region are aimed at enhancing service capabilities and accelerating clinical trial timelines, making Europe an attractive destination for omics-based research.
• The Asia Pacific region is expected to witness the highest CAGR over the forecast period. The region’s market growth is driven by continual advances in clinical research and a favorable trial environment. Countries in this region offer a low cost per patient, a diverse genetic pool, and an easily recruitable patient base, making them ideal for conducting large-scale omics-based trials.
• In the Middle East and Africa (MEA), the omics-based clinical trials market is also projected to grow at a promising rate. Rising incidence of chronic diseases and the increasing focus on healthcare quality are key drivers. MEA is becoming an emerging hub for clinical research due to its diverse population, improved healthcare accessibility, and a growing need for innovative treatments that cater to region-specific medical needs.

Order a free sample PDF of the Omics-based Clinical Trials Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 32.64 billion
• 2030 Projected Market Size: USD 51.77 billion
• CAGR (2025-2030): 8.02%
• North America: Largest market in 2024
• Saudi Arabia: Fastest growing market

Key Companies & Market Share Insights

Key players operating in the omics-based clinical trials market are undertaking various initiatives to strengthen their market presence and increase the reach of their services. Companies such as Parexel International Corporation, Pharmaceutical Product Development (PPD), ICON plc are continuously involved in expanding their facilities, collaborating, and engaging in partnerships, mergers, and acquisitions of companies. These are key strategic initiatives that are influencing industry dynamics. For instance, in June 2024, Thermo Fisher Scientific Inc. announced the launch of new solutions designed to accelerate research workflows at the annual American Society for Mass Spectrometry (ASMS) Conference in California. The latest mass spectrometry and chromatography instruments, along with advanced software solutions, offers researchers the chance to achieve deeper analytical insights with tailored flexibility. This innovation improves productivity and efficiency, ultimately accelerating translational research workflows and driving the advancement of omics-based clinical trials. 

Key Players

• Parexel International (MA) Corporation
• Thermo Fisher Scientific Inc.
• Charles River Laboratories
• ICON plc
• SGS Société Générale de Surveillance SA
• Eli Lilly and Company
• Pfizer Inc.
• Laboratory Corporation of America
• Novo Nordisk A/S
• Rebus Biosystems, Inc.

Browse Horizon Databook on Omics-based Clinical Trials Market – Global Omics-based Clinical Trials Size & Outlook

Conclusion

The omics-based clinical trials market is experiencing robust growth, fueled by advances in genomics, proteomics, and metabolomics, along with rising demand for personalized medicine. Regions such as North America and Asia Pacific are leading in adoption due to their technological infrastructure and favorable clinical environments. The dominance of phase III and interventional studies underscores the market’s maturity and depth. Increasing prevalence of cancer and chronic diseases, coupled with strategic industry collaborations, is driving further innovation. With continual technological refinement and a global shift toward individualized therapies, the market is well-positioned for sustainable growth and transformative healthcare outcomes in the coming years.